$LLY News
Last published 5h ago
- 5h agoLLYHIMSNVDANasdaq Jumps Over 4% This Week as Chip Names Drive a Sharp Midweek RallyPR NewswireStock Preachers News Commentary - Stocks staged a broad midweek advance, with the Nasdaq Composite climbing 2.06% on the session and 4.08% for...
- 9h agoLLYNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesityPR NewswireNearly three times as many patients taking Taltz and Zepbound achieved ≥50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to...
- 1d agoLLYLife doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waitingPR NewswireEli Lilly and Company (NYSE: LLY) and partner Leanne Morgan today announced the launch of Life Doesn't Slow Down, a new campaign for Lilly's...
- 1d agoNVOLLYFDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, ZepboundCNBCThe agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
- 2d agoNVDAYUMLLYGSK+3As Nvidia probes Jensen Huang affair, here's the board member likely to play a big roleCNBCStephen Neal is the board's lead independent director and head of corporate governance. Experts say how Nvidia handles the probe is crucial to retaining its reputation.
- 2d agoAMGNLLYHIMSIndices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays ElevatedPR NewswireStock Preachers News Commentary - Wall Street opens a new week nursing bruises from a rough stretch that sent every major index lower, with the...
- 2d agoLLYEli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approvalCNBCLilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity.
- 2d agoLLYLilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight lossPR NewswireEli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced positive results from ATTAIN-OSA, a Phase 3 clinical...
- 2d agoNVOLLYIFFCould supplements be the next big opportunity in the GLP-1 weight-loss drug boom?CNBCNovonesis is exploring whether gut health supplements could benefit patients taking GLP-1 weight-loss drugs, opening up a potentially lucrative new market.
- 2d agoLEGNGILDAZNMCK+4Gabelli Releases Agenda for 8th Annual Healthcare SymposiumGlobeNewswirePALM BEACH, Florida, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Gabelli today released the agenda for its 8th Annual Healthcare Symposium to be held this Friday, November 13 in conjunction with Columbia Business School at the
- 5d agoAAPLNVDAIBMJNJ+4U.S. Reshoring and Nearshoring: A Sustainable Economic TailwindStifel InsightsMarket Sight | Lines Investors are increasingly worried about market levels and the possibility of an artificial intelligence (AI) “bubble.” Despite the worries, however, during earnings calls and elsewhere, executives are highlighting a powerful, long-term positive theme: making more in America. What began as a reaction to pandemic-era disruptions has evolved into a structural reindustrializatio ...
- 5d agoLLYHIMSLilly and Hims & Hers expand access to FDA-approved Lilly medicinesPR NewswireEli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound...
- 1w agoNVOLLYNovo raises full-year outlook as Wegovy pill sales impressCNBCNovo posted quarterly earnings ahead of expectations early Wednesday as sales of its Wegovy pill blew past estimates
- 1w agoPNGAFRHHBYNVOVKTX+1Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 BillionGlobeNewswireNEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Peptide-based treatments are attracting growing attention from major pharmaceutical companies as researchers push into new ways to treat diabetes, obesity, cancer, metabolic
- 1w agoLLYQ3 2026 ER Call - ELI LILLY & COEarnings Call TranscriptsLadies and gentlemen, thank you for standing by and welcome to the Eli Lilly 3rd Quarter 2026 Earnings Conference Call. At this time, all participants are on a listen-only mode. Later, we will be conducting a question an
- 1w agoPNGAFNVOHIMSENHA+1The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of GrowthGlobeNewswireNEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Peptide-based medicines are becoming a bigger force in the pharmaceutical industry, and the money flowing into this field reflects that shift. Obesity and diabetes
- 1w agoLLYELI LILLY & Co - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoLLYLilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolioPR NewswireRevenue in Q3 2026 increased 39% to $24.4 billion driven primarily by Mounjaro and Zepbound. Q3 revenue included approximately $900 million of benefits, primarily from $410 million of Jardiance milestones (no further
- 1w agoLLYNOVO-B.COLSEG.LEli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansionCNBCEli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
- 2w agoLLYLilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trialPR NewswireIn adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% vs. 1.8% with Ozempic 2 mg at 80 weeksParticipants taking retatrutide lost an average of 44 lbs to 47 lbs (20% to 21%) vs. 21 lbs (9%) with
- 2w agoLLYPatrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global MarketsPR NewswireYuffa will take on an expanded role as the company scales for its next phase of growth Key highlights:Patrik Jonsson, executive vice president and president, Lilly International, has decided to retire at the end of 2026
- 2w agoLLYNVOAZNRHHBYBillions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two DecadesGlobeNewswireDENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO), AstraZeneca (NYSE:AZN), and Roche (OTCQX:RHHBY) are among the biopharma companies committing billions of
- 2w agoLLYLilly declares fourth-quarter 2026 dividendPR NewswireINDIANAPOLIS, Oct. 26, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the fourth quarter of 2026 of $1.73 per share on outstanding common stock.The dividend
- 2w agoLEGNGILDAZNMCK+5Gabelli To Host 8th Annual Healthcare SymposiumGlobeNewswirePALM BEACH, Florida, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Gabelli is hosting the 8th Annual Healthcare Symposium in conjunction with Columbia Business School on Friday, November 13, 2026, at the Paley Center in New York.
- 2w agoLLYNew data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancerPR NewswireData presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant non-small cell lung cancer
- 2w agoLLYLilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026PR NewswireSofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FRα expression levelsClinical
- 2w agoPFENTHIAVTRLLYHealthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth ChapterGlobeNewswireDENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Healthcare stocks are presenting investors with a mix of pharmaceutical growth stories and catalysts. Pfizer (NYSE:PFE) is drawing renewed attention to
- 2w agoLLYLilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020PR NewswireFirst Lilly site to produce both active pharmaceutical ingredients and finished medicines in a fully integrated facilitySite will create 650 high-wage jobsINDIANAPOLIS, Oct. 22, 2026 /PRNewswire/ -- Eli Lilly and
- 3w agoLLYLilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitisPR NewswireBuilding on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansion for pediatric ulcerative colitis More than 80% of
- 3w agoLLYLilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) CongressPR NewswireFirst Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentationUpdated first-line data for olomorasib, an
- 3w agoKMBWMLLYSOXX+1Jim Cramer says this week's AI sell-off offers a crucial lesson for investorsCNBCCNBC’s Jim Cramer said Thursday’s AI sell-off underscores the importance of owning stocks outside the market’s hottest trade.
- 3w agoLLYLilly confirms date and conference call for third-quarter 2026 financial results announcementPR NewswireINDIANAPOLIS, Oct. 15, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its third-quarter 2026 financial results on October 29, 2026. Lilly will also conduct a conference call that day with the
- 3w agoLLYNew composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one yearPR NewswireIn LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by simultaneous symptomatic, endoscopic and histologic
- 4w agoIBMLLYLMTRTX+1Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver SlidePR NewswireStock Preachers News Commentary VANCOUVER, BC, Oct. 14, 2026 /CNW/ -- Stocks skidded midweek as the Nasdaq Composite dropped 449 points, or 1.65%, to 26,755.24, pulling its weekly loss to 2.23%. The S&P 500 fell
- 4w agoEXELGMABONCYRVMD+1Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research AgendaPR NewswireSAN DIEGO, Oct. 14, 2026 /CNW/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with
- 4w agoWMTNVOLLYWalmart to cover some GLP-1s, inhalers and insulin for employees at no cost as it expands benefitsCNBCWalmart will offer Novo's Ozempic and Lilly's Mounjaro without charge for people with Type 2 diabetes after a new prior authorization.
- 1mo agoCNILLYRTXSAPRecord Highs Beckon for Big Caps as Small Caps Lag and Deal Flow BuildsPR NewswireStock Preachers News Commentary NEW YORK, Oct. 9, 2026 /CNW/ -- Large caps closed out the week near record territory, with the S&P 500 and Nasdaq Composite both finishing higher even after a rocky start to the week.
- 1mo agoLLYNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesityPR NewswireExploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO studyINDIANAPOLIS, Oct. 9, 2026
- 1mo agoCNIIBMLLYRTX+1Nasdaq and S&P Hold Weekly Gains as Small Caps and Dow Slip MidweekPR NewswirePITTSBURGH, Oct. 7, 2026 /CNW/ -- Stock Preachers Market Commentary - Major averages split this week as the Nasdaq Composite and S&P 500 held onto gains while the Dow Jones Industrial Average and Russell 2000 turned
- 1mo agoCNXUSOLVVCELAXGN+1Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.GlobeNewswireRENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a
- 1mo agoRTXLLYIBMIART+1Nasdaq Hits Fresh Highs While Dow Slips and Small Caps Struggle for DirectionPR NewswireStock Preachers News Commentary - Wall Street closed out the week split down the middle, with the Nasdaq Composite punching to a 27,190.86 close on a ...
- 1mo agoLLYLilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditionsPR NewswireEli Lilly and Company (NYSE: LLY) will present new data across its dermatology portfolio at the 2026 Fall Clinical Dermatology Conference taking...
- 1mo agoLLYLilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLLPR NewswireEli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca ...
- 1mo agoLLYNVOWhy Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1sCNBCEli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
- 1mo agoHYFTABCLLLYTWST+1AI Drug Discovery Forecasts Vary Widely as Sector Shifts to DeploymentPR NewswireTowards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound...
- 1mo agoMU.DJI.IXICMETA+7The Dow's rough month, Micron's revenue surge, Google launches Gemini 4 and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
- 1mo agoLLYLilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular diseasePR NewswireEli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from post-hoc analyses of ATTAIN-1 showing that...
- 1mo agoLLYLilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes studyPR NewswireEli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating...
- 1mo agoLLYLilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetesPR NewswireEli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive results from a Phase 2b...
- 1mo agoLLYNew Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitisPR NewswireEli Lilly and Company (NYSE: LLY) today announced that EBGLYSS (lebrikizumab-lbkz) monotherapy met its primary and secondary endpoints at Week 16 in...